Endeavor BioMedicines Launches with $62 Million Series A Financing and Mission to Reverse the Course of Devastating Pulmonary Disease
PRIVATEJan 07, 2021
Amount Raised
$62 Million
Round Type
Series A
San Diego
Description
Endeavor BioMedicines, a biotechnology company developing new treatments targeting the underlying causes of pulmonary fibrosis, today announced it has raised $62 million in a Series A financing. The round was led by Omega Funds, Longitude Capital and Endeavor’s management. Proceeds from the financing will be used to advance taladegib, an inhibitor of the Hedgehog pathway, into two Phase 2 clinical studies for the treatment of idiopathic pulmonary fibrosis (IPF) in 2021.
Who to call at Endeavor Bio Medicines, and when
A new round usually means Endeavor Bio Medicines is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Endeavor Bio Medicines raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Endeavor Bio Medicines, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Endeavor Bio Medicines
Location
San Diego, California, United States
About
Endeavor BioMedicines is developing new treatments targeting the underlying causes of pulmonary fibrosis. The company is developing taladegib, a small-molecule inhibitor of the Hedgehog signaling pathway, that is being investigated for the treatment of idiopathic pulmonary fibrosis (IPF). By targeting this underlying cause of disease, taladegib has the potential to halt and even reverse IPF. Endeavor is supported by leading investors Omega Funds and Longitude Capital. More information is available at www.endeavorbiomedicines.com.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Endeavor Bio Medicines raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
San Diego